Baird raised the firm’s price target on DexCom (DXCM) to $112 from $105 and keeps an Outperform rating on the shares. The firm updated its model following solid Q2 results and where guidance looks conservative.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $102 from $95 at Oppenheimer
- Dexcom’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- Dexcom Reports Strong Q2 2025 Growth and Leadership Change
- Dexcom’s Strong Financial Performance and Strategic Positioning Justify Buy Rating
- Closing Bell Movers: Microsoft jumps 9%, Meta up 12% on earnings beats